Three “Remarkable” Studies Say Clogged Pores May Cause ALS; Drug Targets ID’d – Bioscience Technology

Bioscience TechnologyThree “Remarkable” Studies Say Clogged Pores May Cause ALS; Drug Targets ID’dBioscience TechnologyThese, too, showed clumps of RanGAP and C9 RNA stuck just outside nuclei. In more fly and iPSC experiments, Rothstein’s team added an antisense oligonucleotide engineered to cling to C9 RNA—and keep it from clinging to RanGAP. The clogged pores …

Read More

Isis Pharmaceuticals’ Collaboration to Discover and Develop Antisense Drugs … – MarketWatch

Smarter AnalystIsis Pharmaceuticals’ Collaboration to Discover and Develop Antisense Drugs …MarketWatchISIS PHARMACEUTICALS’ FORWARD-LOOKING STATEMENTThis press release includes forward-looking statements regarding Isis’ alliance with AstraZeneca, Isis’ research, development and commercial opportunities in developing antisense drugs to treat …Isis-AstraZeneca Collaboration For Antisense Drugs Gets HSR ClearanceNasdaqall 18 news articles »

Read More

Public Release: 10-Sep-2015 Identified genetic interaction offers possible new … – EurekAlert (press release)

EurekAlert (press release)Public Release: 10-Sep-2015 Identified genetic interaction offers possible new …EurekAlert (press release)According to the UC San Diego team, the next step is to conduct preclinical studies to assess the efficacy and safety of antisense oligonucleotides – strands of synthesized DNA or RNA that can prevent transfer of genetic information – which might …and more »

Read More

Vetr Inc. Downgrades ISIS Pharmaceuticals to Buy (ISIS) – Dakota Financial News

Vetr Inc. Downgrades ISIS Pharmaceuticals to Buy (ISIS)Dakota Financial NewsIsis Pharmaceuticals, Inc. (NASDAQ:ISIS) is a Ribonucleic acid-targeted (RNA-targeted) drug discovery and development company. The Company is concentrated to find and develop antisense drugs. The antisense drugs are used to take care of a range of …ISIS Pharmaceuticals Lowered to “Buy” at Vetr Inc. (ISIS)Watch List Newsall 2 news articles »

Read More

Antisense RNAi Therapeutics Deals Value Approach $5.6B in Landmark 2014 – Drug Discovery & Development

Drug Discovery & DevelopmentAntisense RNAi Therapeutics Deals Value Approach $5.6B in Landmark 2014Drug Discovery & DevelopmentSource: Shutterstock The deals market for antisense RNA interference (RNAi) therapeutics witnessed a record year in 2014, with a total value of almost $5.6 billion across 59 transactions, by far the largest deal value ever seen in this space, according …and more »

Read More

2014 Record Year for Antisense RNAi Therapeutics Deals – Pharmaceutical Executive (press release) (registration) (blog)

2014 Record Year for Antisense RNAi Therapeutics DealsPharmaceutical Executive (press release) (registration) (blog)The deals market for antisense RNA interference (RNAi) therapeutics witnessed a record year in 2014, with a total value of almost $5.6 billion across 59 transactions, by far the largest deal value ever seen in this space, according to research and …and more »

Read More

Drug Delivery in Central Nervous System Diseases – Technologies, Markets and … – PR Newswire (press release)

Drug Delivery in Central Nervous System Diseases – Technologies, Markets and …PR Newswire (press release)Cell, gene and antisense therapies are not only innovative treatments for CNS disorders but also involve sophisticated delivery methods. RNA interference (RNAi) as a form of antisense therapy is also described. The role of drug delivery is depicted in …and more »

Read More

Global Antiviral Therapeutics Markets 2015 – Technologies and Companies … – PR Newswire (press release)

Global Antiviral Therapeutics Markets 2015 – Technologies and Companies …PR Newswire (press release)… vaccines, MAbs and innovative approaches that include immunological and use of other technologies such as gene therapy, antisense, RNAi and nanobiotechnology. Antiviral markets are estimated starting with 2014 with projections up to the year 2024.and more »

Read More

SunTrust Raises Sarepta Therapeutics Price Target to $36.00 (SRPT) – Dakota Financial News

OctaFinance.comSunTrust Raises Sarepta Therapeutics Price Target to $36.00 (SRPT)Dakota Financial NewsSarepta Therapeutics, Inc. is a biopharmaceutical firm. The Firm is centered on the discovery and development of exceptional ribonucleic acid (NASDAQ:SRPT) drug candidates, including its lead DMD product candidate, eteplirsen, which will be an …Sarepta Therapeutics Stock Rating Upgraded by RBC Capital (SRPT)Financial Wisdom WorksWhy Need to Watch: CONSOL Energy Inc. (NYSE:CNX), QUALCOMM, Inc. (NASDAQ:QCOM …Stock Transcriptall 42 news articles »

Read More

Sarepta Therapeutics Price Target Increased to $36.00 by Analysts at … – Dakota Financial News

Sarepta Therapeutics Price Target Increased to $36.00 by Analysts at …Dakota Financial NewsThe Business is centered on the discovery and development of unique ribonucleic acid (NASDAQ:SRPT) drug candidates, including its lead DMD merchandise candidate, eteplirsen, which can be an antisense PMO healing in Phase III clinical development …Cowen and Company Reiterates Hold Rating for Sarepta Therapeutics (SRPT)WKRB NewsWhy Need to Watch: CONSOL Energy Inc. (NYSE:CNX), QUALCOMM, Inc. (NASDAQ:QCOM …Stock Transcriptall 36 news articles »

Read More

Common gene mutation may cause brain damage associated with ALS and FTD – News-Medical.net

Bioscience TechnologyCommon gene mutation may cause brain damage associated with ALS and FTDNews-Medical.netIn another set of experiments using the fly and human stem cells, the scientists added antisense oligonucleotides, bits of RNA designed to bind to the repetitive RNA strands, blocking them from interacting with the RanGAP protein. The jammed up nuclear …Treating Dementia And ALS: New Molecular Therapy May Help Reverse Brain DamageMedical Dailyall 28 news articles »

Read More

Treating Dementia And ALS: New Molecular Therapy May Help Reverse Brain Damage – Medical Daily

Medical DailyTreating Dementia And ALS: New Molecular Therapy May Help Reverse Brain DamageMedical DailyIn fly and human stem cells, the researchers used antisense oligonucleotides — bits of RNA — to block RNA strands from impacting the RanGAP protein. This cleared up the traffic jam, which allowed proteins to move into the cell nuclei. “We still don’t …Jammed up cellular highways may initiate dementia and ALSMedical Xpressall 13 news articles »

Read More

Sarepta Therapeutics Earns “Buy” Rating from Roth Capital (SRPT) – Dakota Financial News

Bidness ETCSarepta Therapeutics Earns “Buy” Rating from Roth Capital (SRPT)Dakota Financial NewsThe Company is focused on the discovery and development of exceptional ribonucleic acid (NASDAQ:SRPT) drug candidates, including its lead DMD product candidate, eteplirsen, which can be an antisense PMO healing in Phase III clinical development for …Sarepta Therapeutics Inc 50% Potential Upside Now Implied by Piper JaffrayDirectorsTalk InterviewsSarepta Therapeutics Given Buy Rating at Roth Capital (SRPT)Financial Wisdom Worksall 58 news articles »

Read More

Global Antisense and RNAi Therapeutics Market 2015 estimated to grow at a … – Medgadget.com (blog)

Medgadget.com (blog)Global Antisense and RNAi Therapeutics Market 2015 estimated to grow at a …Medgadget.com (blog)Antisense and RNAi therapeutics are new innovative therapeutics options that are used in the treatment of serious chronic and rare diseases. RNAi is a RNA-based gene silencing process in which RNA molecules inhibit gene expression by destructing …and more »

Read More

Make antisense of lncRNA knockdowns – Scientist Live

Make antisense of lncRNA knockdownsScientist LiveIntegrated DNA Technologies (IDT) will host an informative webinar, entitled ‘Knockdown of lncRNAs: exploring RNAi and antisense oligo methods’, on Tuesday, August 25, 2015. Kim Lennox, a research scientist at IDT and expert in the suppression of gene …

Read More